Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "PATH"

1239 News Found

CCRH and Adamas University sign MoU to advance homoeopathy research
News | March 12, 2025

CCRH and Adamas University sign MoU to advance homoeopathy research

This MoU marks a significant milestone in interdisciplinary research, paving the way for scientific advancements in homoeopathy


Metropolis Healthcare to acquire Agra's Scientific Pathology
Healthcare | March 04, 2025

Metropolis Healthcare to acquire Agra's Scientific Pathology

Metropolis Clinical Pathology will acquire and operate all laboratories and collection centers of Scientific Pathology in Agra and neighbouring towns through a slump sale transaction


Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
News | February 17, 2025

Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

No safety signals related to the vaccine candidate were identified


Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens
Clinical Trials | January 13, 2025

Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens

The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure


Antara partners with Dr. Lal PathLabs to strengthen its geriatric care services
Healthcare | December 24, 2024

Antara partners with Dr. Lal PathLabs to strengthen its geriatric care services

This curated geriatric care package - Varishtha Aarogya Vardaan -- includes a comprehensive range of essential blood tests specifically curated for seniors.


Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy
Drug Approval | December 14, 2024

Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy

Final decision from the European Commission is anticipated within the coming months


Dr. Lal PathLabs Q2 FY25 consolidated net profit up at Rs. 129.2 Cr
News | October 25, 2024

Dr. Lal PathLabs Q2 FY25 consolidated net profit up at Rs. 129.2 Cr

Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024


Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
News | August 31, 2024

Thyrocare to acquire diagnostic and pathological services business of Vimta Labs

Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025